Mesoblast Limited ASX:MSB

Mesoblast is an Australian regenerative medicine company developing cell-based therapies for inflammatory diseases.

We are looking to buy the breakout of the 2.60 resistance with a stoploss just below the last week's low at 2.35. Profit target 3.28

Mesoblast ASX:MSB - constructive price action